Rocket Pharmaceuticals, Inc. is a clinical-stage biotechnology company. The Company is focused on developing gene therapy treatment options for rare, devastating diseases. The Companyâ€™s multi-platform development approach applies the well-established lentiviral vector (LVV) and adeno-associated viral vector (AAV) gene therapy platforms. The Companyâ€™s lead clinical program is a LVV-based gene therapy for the treatment of Fanconi Anemia (FA), a genetic disease that leads to bone marrow failure and potentially cancer. Its additional pipeline programs for bone marrow-derived disorders are for Pyruvate Kinase Deficiency (PKD), Leukocyte Adhesion Deficiency-I (LAD-I) and Infantile Malignant Osteopetrosis (IMO). The Company is also developing an AAV-based gene therapy program for pediatric heart failure indication, Danon disease.
Number of employees : 57 people.
|Vote ||Quantity||Free-Float||Company-owned shares||Total Float
|RTW Investments LP ||16,812,491||
|Tang Capital Management LLC ||2,965,485||
|Perceptive Advisors LLC ||2,189,010||
|Adage Capital Management LP ||2,157,739||
|The Vanguard Group, Inc. ||1,824,334||
|Westfield Capital Management Co. LP ||1,711,501||
|Wellington Management Co. LLP ||1,688,990||
|SSgA Funds Management, Inc. ||1,588,389||
|Eventide Asset Management LLC ||1,550,000||
|Cormorant Asset Management LP ||1,468,550||
|Company contact information|
Rocket Pharmaceuticals, Inc.
The Empire State Building
350 5th Avenue
New York, NY 10118
Phone : +1.646.440.9100
Fax : +1.646.224.9585
Web : http://www.rocketpharma.com
Sector Bio Therapeutic Drugs
Connections : Rocket Pharmaceuticals, Inc.